An international team of scientists has created an experimental COVID-19 antiviral therapy that has been shown to minimize the viral load by 99.9% and improve mice survival rates.
The next-generation approach to antiviral therapy, developed by researchers from Griffith University's Menzies Health Institute Queensland (MHIQ) and the Beckman Research Institute in Los Angeles, is intended to treat both the initial virus that causes COVID-19 and any potential variants. Moreover, Tamiflu, Zanamivir, and Remdesivir antiviral treatments will be used as they help in healing faster from COVID-19.
The therapy employs a gene-silencing RNA technology known as siRNA (small-interfering RNA) to specifically target the virus genome and also preventing it from replicating. The findings indicate that siRNA-nanoparticle formulations may be used to treat COVID-19 patients as well as potential coronavirus infections by directly targeting the virus' genome. This therapy is quite cost-effective and scalable.
Disclaimer: We don't claim any ownership of the news published on this page. The ownership remains with the news publisher mentioned as the source. Read Full News Publishing Policy
